ESMO expert Rodrigo Dienstmann discusses the MONARCH 3 trial investigating the addition of the CDK4/6 inhibitor abemaciclib to aromatase inhibitor therapy in women with advanced hormone receptor-positive, HER2-negative breast cancer.
26-09-2017 | ESMO 2017 | Video